Committee hears broad support for LD2151 to fund FQHC pharmacies in ‘pharmacy deserts’
Loading...
Summary
Senator Cameron Rennie and many health centers, unions, physicians, and advocates urged funding a $4 million grant program (LD2151) to help Federally Qualified Health Centers develop in‑house pharmacies to fill gaps in rural and underserved areas. Witnesses cited pharmacy closures, access for non‑drivers, and start‑up cost estimates.
Senator Cameron Rennie presented LD2151, proposing $4,000,000 in one‑time funding to create a DHHS‑administered grant program that helps Federally Qualified Health Centers (FQHCs) establish or expand in‑house pharmacy services.
"In most Maine counties, more than 50% of residents now live in a pharmacy desert," Rennie said, and witnesses described the practical consequences: patients who cannot travel, those with urgent prescriptions that cannot wait for mail order, higher risk of hospitalizations when medications are delayed, and workforce challenges for community health providers.
Multiple FQHC chiefs, clinicians, union representatives and legal advocates testified in support. Colleen Elias, CEO of Community Clinical Services, explained that for many patients prescription access depends on reliable local services, not mail order, and that an on‑site pharmacy improves medication adherence and safety. FQHCs reported pro forma startup estimates ranging from roughly $550,000 to $750,000 per new pharmacy, depending on build‑out, staffing and technology needs.
Witnesses and committee members discussed program targeting (prioritizing communities with greatest distance or transportation barriers), how to structure grant criteria, interactions with existing federal Rural Health Transformation or other funds, and the need for clear rules and timelines to avoid repeating a prior rescission of previously allocated funds. Sponsors and several members emphasized the prior unanimous committee support in 2024 and urged restoring funding and completing rules: the bill includes an implementation deadline for rules in Section 5 (no later than December 15, 2026).
Committee members requested additional specificity in rules to prioritize the highest‑need sites and asked HHS and sponsors for grant criteria and expected timelines for first prescription delivery once grants are awarded. No committee vote was taken at the hearing; members signaled interest in a work session with detailed rule language and prioritization criteria.
